Assistant Professor of Nanomedicine, Academic Institute
Assistant Member, Research Institute
Weill Cornell Medical College
Dr. Corrine Ying Xuan Chua obtained her Bachelor of Science degree in Microbiology magna cum laude in 2006 from the University of Louisiana at Lafayette in Lafayette, LA. In 2009, she received her master's degree in Cellular and Structural Biology from the University of Texas Health Science Center at San Antonio in San Antonio, TX. Her master's thesis was focused on studying mechanisms of therapeutic resistance in alveolar rhabdomyosarcoma, a rare childhood muscle cancer. She researched different preclinical therapeutics in genetically engineered murine cancer models of alveolar rhabdomyosarcoma.
In 2015, she received her Ph.D. degree in Cancer Biology summa cum laude from the University of Texas MD Anderson Cancer Center, Houston, TX. She focused on investigating oncogenic pathways and identifying therapeutically targetable factors for glioma treatment. There she achieved several accomplishments for this work, including publications as first- or co-author in a peer-reviewed journals (Oncogene, PNAS, Journal of Pathology) and awards such as the Caroline Ross Endowed Fellowship Award, Professor Alexander Wang Memorial Scholarship Award and UT Graduate School-related awards.
Dr. Chua joined the Department of Nanomedicine at Houston Methodist Research Institute as a postdoctoral fellow the under the mentorship of Dr. Alessandro Grattoni in 2016. Her research activities as a postdoctoral fellow involved drug delivery using nanotechnology-based implants for a variety of therapeutic indications including cancer and HIV.
She is currently a Research Assistant Professor in the Department of Nanomedicine at Houston Methodist Research Institute and an Assistant Professor of Nanomedicine Research in Medicine at Weill Cornell Medical College, New York, NY.
Dr. Chua’s research interest is to develop alternative strategies for cancer treatment, with a primary focus on nanofluidics-based intratumoral delivery of immunotherapy to improve therapeutic efficacy and minimize adverse effects of systemic treatment. She is also working on developing a therapeutic cancer vaccine via an implantable platform for continuous antigen-specific immune activation against tumors.